This study retrospectively investigated the impact of interleukin-1 receptor-associated kinase-3 (IRAK-3/IRAK-M) silencing by methylation on the likelihood of multiple sclerosis (MS) activity. This cross-sectional study included 90 patients with MS: 45 with active disease (Group 1), 45 in remission (Group 2), and 45 healthy controls. The study included quantitation of IRAK-3 methylation index (MI%), IRAK-3 mRNA, and myeloid differentiation factor88 (MyD88) and assessment of NF-κB activity. IRAK-3 MI% was significantly higher in group 1 compared to group 2, accompanied by lower IRAK-3 mRNA expression, elevated circulating MyD88, and increased NF-κB activity. IRAK-3 MI% correlated negatively with its transcript and positively with MyD88 and NF-κB activity. A logistic regression model was created to predict active demyelination. The C-index was 0.924, which indicates a very strong prediction model. Within the limitations of current work, IRAK-3 methylation level seems to be a promising candidate biomarker for identifying MS patients at risk of relapse.
Keyphrases
- multiple sclerosis
- mass spectrometry
- ms ms
- signaling pathway
- dna methylation
- genome wide
- lps induced
- pi k akt
- oxidative stress
- toll like receptor
- white matter
- bone marrow
- rheumatoid arthritis
- dendritic cells
- binding protein
- tyrosine kinase
- inflammatory response
- high resolution
- systemic lupus erythematosus
- protein kinase
- acute myeloid leukemia
- immune response
- disease activity
- ulcerative colitis
- tandem mass spectrometry